Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Plasma-Based Algorithm Accurately Predicts Likelihood of Developing Alzheimer’s Disease

By LabMedica International staff writers
Posted on 31 May 2021
A team of Swedish researchers has created an algorithm for use by physicians lacking access to advanced diagnostic instruments, which accurately predicts future risk of developing Alzheimer’s disease (AD).

Early and accurate diagnosis of AD is necessary to take advantage of a new generation of drugs designed to slow down the progression of the disease.

In this regard, investigators at Lund University (Sweden) hypothesized that the combination of plasma phosphorylated tau protein (P-tau) and other accessible biomarkers might provide accurate prediction about the risk of developing AD. They tested this theory by analyzing blood samples from 340 participants with subjective cognitive decline and mild cognitive impairment from the Swedish BioFINDER study and 543 participants from the North American Alzheimer’s Disease Neuroimaging Initiative (ADNI). Plasma P-tau, plasma Abeta42/Abeta40, plasma neurofilament light, APOE genotype, brief cognitive tests, and an AD-specific magnetic resonance imaging measure were examined using progression to AD as outcome.

Results revealed that within four years of the analysis, plasma P-tau217 predicted AD accurately (area under the curve (AUC) = 0.83) in the BioFINDER group. Combining plasma P-tau217, memory, executive function and APOE produced higher accuracy (AUC = 0.91). In the ADNI group, this model had similar AUC (0.90) using plasma P-tau181 instead of P-tau217.

The diagnostic model was used to predict the probability of an individual progressing to AD. Within two and six years, similar models had AUCs of 0.90–0.91 in both cohorts. Significantly, measuring cerebrospinal fluid P-tau, Abeta42/Abeta40, and neurofilament light instead of plasma biomarkers did not significantly improve the accuracy. Furthermore, this simple prognostic algorithm was significantly more accurate than clinical predictions by dementia experts who examined the patients, but did not have access to data generated by the algorithm.

“A combination of a simple blood test (measuring a variant of the tau protein and a risk gene for Alzheimer's) and three brief cognitive tests that only take 10 minutes to complete, predicted with over 90% certainty which patients would develop Alzheimer's dementia within four years. This simple prognostic algorithm was significantly more accurate than the clinical predictions by the dementia experts who examined the patients, but did not have access to expensive spinal fluid testing or PET scans,” said senior author Dr. Oskar Hansson, professor of neurology at Lund University. “The algorithm will enable us to recruit people with Alzheimer's at an early stage, which is when new drugs have a better chance of slowing the course of the disease.”

The Alzheimer’s disease diagnostic algorithm was described in the May 24, 2021, online edition of the journal Nature Medicine.

Related Links:
Lund University


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.